Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas (SIOP-LGG-2004)

April 19, 2018 updated by: Astrid K. Gnekow, Societe Internationale d'Oncologie Pediatrique

Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This clinical trial is studying giving radiation therapy or combination chemotherapy to see how well it works in treating patients with clinically or radiologically progressive low-grade gliomas.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

  • Provide a comprehensive treatment strategy for children and adolescents with low-grade glioma of all tumour locations and histologies.
  • Provide standardized treatment indication and treatment recommendations for non-surgical therapy in children and adolescents with low grade glioma without and with associated neurofibrosis-type 1 (NF1) at diagnosis or after observation.
  • Determine overall, event-free, and progression-free survival.
  • Radiotherapy arm: a. Determine progression free survival in older children without NF1 treated with radiotherapy using modern techniques for planning and treatment. b. Determine the reduction of the rate and intensity of possible late effects of therapy to the organs at risk by optimized planning and treatment.
  • Chemotherapy arm: a. Determine progression free survival for younger children without NF1 treated with chemotherapy and randomized to either the 2-drug or the 3-drug induction regimen. b. Determine the distribution of response at week 24 (after induction) for younger children without NF1 treated with chemotherapy and randomized to either the 2-drug or the 3-drug induction regimen. c. Determine progression free survival for children with NF1treated with chemotherapy.
  • Determine the influence of clinical and histological findings on overall survival, progression-free and event-free survival in these patients.
  • Determine prospectively the late effects of tumor and therapy in these patients.

OUTLINE: This is a partially randomized, open-label, multicenter study.

Children with completely resected tumors, incompletely resected tumors, or those with clinically/neuroradiologically diagnosed tumors, who do not have severe symptoms at diagnosis, are only observed during follow-up.

Children with unresectable/incompletely-resectable tumors, or those with relapsed disease and those observed following incomplete initial resection or neuroradiologic diagnosis and clinical and/or neuro-radiologic progression receive non-surgical therapy. This non-surgical therapy is either chemotherapy (for children younger than 8 years and those with neurofibrosis-type 1 [NF1]) or radiotherapy (for children older than 8 years).

  • Chemotherapy: Within the chemotherapy arm, patients without NF1 are randomized to receive 1 of 2 induction chemotherapy regimens. Patients with NF1 receive the two-drug induction therapy as in arm I.

    • Arm I (two-drug induction therapy [vincristine-carboplatin] ): Patients receive induction therapy comprising vincristine IV on day 1 of weeks 1-10 and weeks 13, 17, and 21 and carboplatin IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 17, and 21.
    • Arm II (three-drug induction therapy [vincristine-carboplatin-etoposide]): Patients receive vincristine and carboplatin as in two-drug induction therapy. Patients also receive etoposide IV over 1 hour on days 1-3 of weeks 1, 4, 7, and 10.

Beginning in week 25, all patients in the chemotherapy arm receive consolidation therapy comprising vincristine IV on days 1, 8, and 15 and carboplatin IV over 1 hour on day 1. Treatment repeats every 6 weeks for 9 courses. Patients experiencing disease progression or an allergic reaction to carboplatin receive vincristine IV on days 1, 8, and 15 and either cyclophosphamide IV over 1 hour on day 1 or cisplatin IV over 3 hours on days 1 and 2. Treatment repeats every 6 weeks for 5 courses. All patients in the chemotherapy arm receive a total of 18 months of treatment.

  • Radiotherapy: Conventional external beam fractionated radiotherapy is given at standard doses for children receiving radiotherapy. Brachytherapy can be given, if tumors are suitable for this type of treatment.

After completion of study treatment, patients are followed periodically for 10 years.

PROJECTED ACCRUAL: A total of 520 patients will be accrued for the randomized arm of this study.

Study Type

Interventional

Enrollment (Actual)

3417

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Wien, Austria, 1090
        • Allg. Krankenhaus der Stadt Wien Universitaets-Kinderklinik
  • Belgium
      • Ghent, Belgium, B-9000
        • Universitair Ziekenhuis Gent
  • Croatia
      • Zagreb, Croatia, 10000
        • Children's Hospital Zagreb
  • Denmark
      • Aalborg, Denmark, 9100
        • Aalborg Hospital
  • France
      • Villejuif, France, F-94805
        • Institut Gustave Roussy
  • Germany
      • Augsburg, Germany, DOH-86156
        • Klinikum Augsburg
  • Italy
      • Padova, Italy, 35128
        • Azienda Ospedaliera di Padova
  • Norway
      • Tromso, Norway, N-9037
        • University of Tromso
  • Poland
      • Warsaw, Poland, 04-736
        • Children's Memorial Health Institute
  • Portugal
      • Porto, Portugal, 4200
        • Hospital San Joao
  • Switzerland
      • Zurich, Switzerland, CH-8032
        • University Children's Hospital
  • United Kingdom
    • England
      • Leeds, England, United Kingdom, LS9 7TF
        • Leeds Cancer Centre at St. James's University Hospital
      • Nottingham, England, United Kingdom, NG7 2UH
        • Queen's Medical Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

DISEASE CHARACTERISTICS:

  • Histologically confirmed low-grade glioma, of 1 of the following histologic subtypes:

    • Pilocytic astrocytoma I° and variants
    • Subependymal giant cell astrocytoma I°
    • Dysembryoplastic neuroepithelial tumor I°
    • Desmoplastic infantile ganglioglioma I°
    • Ganglioglioma I° and II°
    • Pleomorphic xanthoastrocytoma II°
    • Oligodendroglioma II°
    • Oligoastrocytoma II°

    • Astrocytoma II°

      • Fibrillary astrocytoma II°
      • Protoplasmatic astrocytoma II°
      • Gemistocytic astrocytoma II°
  • Children with chiasmatic-hypothalamic tumors may be eligible without histological diagnosis, if neuroradiologic findings meet unequivocal criteria for the presence of a low-grade glioma

  • Primary tumor localization: intracranial and/or spinal cord

    • No diffuse intrinsic tumors of the pons, even if histologically an astrocytoma I° or II° is diagnosed

      • Exception: pontine glioma II° in neurofibromatosis type 1 (NF1) disease allowed
  • Children presenting with disseminated low-grade glioma will be eligible for the study
  • All eligible patients without NF1 disease receiving chemotherapy as their first nonsurgical therapy are eligible for randomization
  • Children are eligible for the trial regardless of the presence of associated genetic disease: NF1 disease will be the prominent one, all children with NF1 disease are entered into the study arm III in case of an indication for nonsurgical therapy

  • Patients presenting with rare intracranial neoplasms of low-grade malignancy, but nonglial origin, may be followed according to the low-grade glioma strategy, but they are not subject of this therapy trial.

    • Data from these patients may be registered to learn about those therapeutic interventions which may prove useful to these patients and to develop separate strategies in the future
    • Patients with choroid plexus papilloma should be entered into the SIOP-CPT study (Prof. Dr. J. Wolff, M.D. Anderson Cancer Center, Houston, Texas)

PATIENT CHARACTERISTICS:

  • No preexisting impairments of health status, making the conduct of the study impossible or ethically unwise
  • No evidence of pregnancy or lactation period
  • Pregnancy has to be prevented in fertile adolescent girls during chemotherapy by reliable contraception methods (e.g., hormonal contraception)

PRIOR CONCURRENT THERAPY:

  • The tumor should not be pretreated with chemotherapy or radiotherapy

    • Children treated with chemotherapy or radiotherapy prior to entering the study will be evaluated separately

      • Previous treatment with steroids is not considered a chemotherapeutic treatment

  • Surgery of any type and extent allowed

    • Prior surgical resection of the tumor allowed
  • Participation in another clinical study concurrently with this study (e.g., endocrinologic study) allowed provided it is not interfering with the present treatment strategy
  • No other concurrent chemotherapy
  • Concurrent medication for associated or other conditions (e.g., hormone replacement, anticonvulsants) that does not containing cytostatic drugs allowed

INCLUSION CRITERIA

  • Age: children and adolescents up to the completion of the 18th year of life.
  • Histology: low grade glioma according to ICD O Code Children with chiasmatic-hypothalamic tumors may be eligible without histological diagnosis, if neuroradiologic findings meet unequivocal criteria for the presence of a low grade glioma.
  • Primary tumor localization: intracranial and/or spinal cord.
  • Dissemination: Children presenting with disseminated low grade glioma will be eligible for the study.
  • Associated conditions: Children are eligible for the trial regardless of the presence of associated genetic disease: Neurofibromatosis NF I will be the prominent one, all children with NF I are entered into the study arm III in case of an indication for non-surgical therapy. Other conditions like Tuberous Sclerosis etc. should be registered and their impact on the course of disease and/or therapy be followed.
  • Primary tumor diagnosis: The tumor should not be pretreated with chemotherapy or radiotherapy.
  • Informed consent: The patient and/or his legal guardian ( parents ) have to have declared their written informed consent to the study.

Randomization: All eligible patients without Neurofibromatosis NF I receiving chemotherapy as their fist non-surgical therapy are eligible for randomization.

EXCLUSION CRITERIA

  • Primary tumor localization: diffuse intrinsic tumors of the pons, even if histologically an Astrocytoma I° or II° is diagnosed.

Exception: pontine glioma II° in NF I patients may be entered into the study.

  • Special diagnosis: Patients presenting with rare intracranial neoplasms of low grade malignancy, but non-glial origin may be followed according to the low grade glioma strategy but they are not subject of this therapy trial. Their data may be registered however, to learn about those therapeutic interventions which may prove useful to these patients and to develop separate strategies in the future. Choroid plexus papilloma should be entered into the SIOP-CPT study.
  • Pretreatment: Children treated with chemo- or radiotherapy prior to entering the study will be evaluated separately. (Previous treatment with steroids is not considered a chemotherapeutic treatment.)
  • Preexisting impairments of health status, making the conduct of the study impossible or ethically unwise.
  • Evidence of pregnancy or lactation period.

Participation in another clinical study: In case the patient participates in another clinical study simultaneously to being enrolled in the study SIOP-LGG 2004, which is not interfering with the present treatment strategy ( e.g. endocrinologic study ), this should be known to the national study chairmen.

Medication: Concomitant medication for associated or other conditions ( e.g. hormone replacement, anticonvulsants ), not containing cytostatic drugs, should be recorded, but is no exclusion criteria.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: vincristine, carboplatin
standard chemotherapy group
Drug: vincristine, carboplatin

vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21

carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21
Active Comparator: vincristine, carboplatin, etoposide
intensified induction chemotherapy group
Drug: vincristine, carboplatin, etoposide

vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21

carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21

etoposide: 100 mg/m² i.v., week 1,4,7,10
Active Comparator: radiation
radiation therapy group
Radiation: radiation therapy

intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks

spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks
No Intervention: Control
Control group: wait and see strategy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Progression-free survival
Time Frame: week 24, and at 1, 3, and 5 years
week 24, and at 1, 3, and 5 years
Event-free survival
Time Frame: week 24 and at 1, 3, and 5 years
week 24 and at 1, 3, and 5 years
Overall survival
Time Frame: week 24 and at 1, 3, and 5 years
week 24 and at 1, 3, and 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Response week 24
Time Frame: week 24
radiological response to therapy (chemotherapy or radiation therapy)
week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Societe Internationale d'Oncologie Pediatrique

Investigators

  • Study Chair: Astrid Gnekow, University Hospital Augsburg

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2004

Primary Completion (Actual)

December 31, 2015

Study Completion (Actual)

May 31, 2017

Study Registration Dates

First Submitted

January 12, 2006

First Submitted That Met QC Criteria

January 12, 2006

First Posted (Estimate)

January 13, 2006

Study Record Updates

Last Update Posted (Actual)

April 20, 2018

Last Update Submitted That Met QC Criteria

April 19, 2018

Last Verified

April 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CDR0000454506
  • 2005-005377-29 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Central Nervous System Neoplasms

Clinical Trials on vincristine, carboplatin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe